These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 22985698)

  • 1. Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics.
    Corchero JL; Gasser B; Resina D; Smith W; Parrilli E; Vázquez F; Abasolo I; Giuliani M; Jäntti J; Ferrer P; Saloheimo M; Mattanovich D; Schwartz S; Tutino ML; Villaverde A
    Biotechnol Adv; 2013; 31(2):140-53. PubMed ID: 22985698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Process technology for production and recovery of heterologous proteins with Pichia pastoris.
    Jahic M; Veide A; Charoenrat T; Teeri T; Enfors SO
    Biotechnol Prog; 2006; 22(6):1465-73. PubMed ID: 17137292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production of recombinant HIV-1 nef protein using different expression host systems: a techno-economical comparison.
    Vermasvuori R; Koskinen J; Salonen K; Sirén N; Weegar J; Dahlbacka J; Kalkkinen N; von Weymarn N
    Biotechnol Prog; 2009; 25(1):95-102. PubMed ID: 19224559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yeast synthetic biology for the production of recombinant therapeutic proteins.
    Kim H; Yoo SJ; Kang HA
    FEMS Yeast Res; 2015 Feb; 15(1):1-16. PubMed ID: 25130199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct ethanol production from hemicellulosic materials of rice straw by use of an engineered yeast strain codisplaying three types of hemicellulolytic enzymes on the surface of xylose-utilizing Saccharomyces cerevisiae cells.
    Sakamoto T; Hasunuma T; Hori Y; Yamada R; Kondo A
    J Biotechnol; 2012 Apr; 158(4):203-10. PubMed ID: 21741417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycosylation control technologies for recombinant therapeutic proteins.
    Gupta SK; Shukla P
    Appl Microbiol Biotechnol; 2018 Dec; 102(24):10457-10468. PubMed ID: 30334089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for the production of difficult-to-express full-length eukaryotic proteins using microbial cell factories: production of human alpha-galactosidase A.
    Unzueta U; Vázquez F; Accardi G; Mendoza R; Toledo-Rubio V; Giuliani M; Sannino F; Parrilli E; Abasolo I; Schwartz S; Tutino ML; Villaverde A; Corchero JL; Ferrer-Miralles N
    Appl Microbiol Biotechnol; 2015 Jul; 99(14):5863-74. PubMed ID: 25616525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant protein production in yeasts.
    Mattanovich D; Branduardi P; Dato L; Gasser B; Sauer M; Porro D
    Methods Mol Biol; 2012; 824():329-58. PubMed ID: 22160907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterologous protein production using the Pichia pastoris expression system.
    Macauley-Patrick S; Fazenda ML; McNeil B; Harvey LM
    Yeast; 2005 Mar; 22(4):249-70. PubMed ID: 15704221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of heterologous proteins in Pichia pastoris: a useful experimental tool in protein engineering and production.
    Daly R; Hearn MT
    J Mol Recognit; 2005; 18(2):119-38. PubMed ID: 15565717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular engineering for therapeutic protein production: product quality, host modification, and process improvement.
    Wells E; Robinson AS
    Biotechnol J; 2017 Jan; 12(1):. PubMed ID: 27933725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Manufacturing of recombinant therapeutic proteins in microbial systems.
    Graumann K; Premstaller A
    Biotechnol J; 2006 Feb; 1(2):164-86. PubMed ID: 16892246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tools to cope with difficult-to-express proteins.
    Saccardo P; Corchero JL; Ferrer-Miralles N
    Appl Microbiol Biotechnol; 2016 May; 100(10):4347-55. PubMed ID: 27079572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production of disulfide-bonded proteins in Escherichia coli.
    Berkmen M
    Protein Expr Purif; 2012 Mar; 82(1):240-51. PubMed ID: 22085722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterologous production of fungal effectors in Pichia pastoris.
    Kombrink A
    Methods Mol Biol; 2012; 835():209-17. PubMed ID: 22183656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in engineered microorganisms for improving metabolic conversion via microgravity effects.
    Huangfu J; Zhang G; Li J; Li C
    Bioengineered; 2015; 6(4):251-5. PubMed ID: 26038088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant protein folding and misfolding in Escherichia coli.
    Baneyx F; Mujacic M
    Nat Biotechnol; 2004 Nov; 22(11):1399-408. PubMed ID: 15529165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the production of membrane proteins in Pichia pastoris.
    Ramón A; Marín M
    Biotechnol J; 2011 Jun; 6(6):700-6. PubMed ID: 21567964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study on the production of human interferon alpha-2b expressed in Escherichia coli.
    Yan Y; Wang X; Wu A; Sun Y
    Chin J Biotechnol; 1996; 12(1):25-9. PubMed ID: 8877111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of a glycoengineered Pichia pastoris cultivation process for commercial antibody production.
    Ye J; Ly J; Watts K; Hsu A; Walker A; McLaughlin K; Berdichevsky M; Prinz B; Sean Kersey D; d'Anjou M; Pollard D; Potgieter T
    Biotechnol Prog; 2011; 27(6):1744-50. PubMed ID: 22002933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.